Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by AT1234on May 14, 2013 2:25pm

265 Views

Post# 21390716

RE: RE: Ratios

Largely agree. Excellent quarter from BRD, but with the sector being out of favor the market does not care, no matter how ridiculous the valuation is. I am happy with the report, gives me confidence to hold what I have and look to add.

I don't think this will be a "long slow sludge" to $1. More likely it won't go anywhere for months, and then will double or more within days. JMHO.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload